Brief: aTyr Pharma Announces Fgfr4 As Receptor Target For Aars Trna Synthetase Fragment
14/06/2022 13:18
June 14 (Reuters) - aTyr Pharma Inc LIFE.O :
* ATYR PHARMA ANNOUNCES FGFR4 AS RECEPTOR TARGET FOR AARS
TRNA
SYNTHETASE FRAGMENT
* ATYR PHARMA INC - SECOND TRNA SYNTHETASE RECEPTOR
IDENTIFIED
FROM COMPANY'S PLATFORM
* ATYR PHARMA INC - FINDINGS SUGGEST AARS FRAGMENT MAY HAVE
THERAPEUTIC POTENTIAL IN FIBROSIS, INFLAMMATION AND CANCER
Source text for Eikon: ID:nGNX2Wg840
Further company coverage: LIFE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on aTyr Pharma
See all newsBrief: Atyr Pharma Announces Research Collaboration With Montefiore Einstein
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan